Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) CFO Sherry Aulin sold 18,709 shares of the company's stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total transaction of $770,997.89. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Xenon Pharmaceuticals Stock Down 1.1 %
Shares of NASDAQ:XENE traded down $0.45 during mid-day trading on Thursday, reaching $38.90. 563,754 shares of the stock were exchanged, compared to its average volume of 388,692. The stock's 50 day simple moving average is $41.93 and its 200-day simple moving average is $40.47. Xenon Pharmaceuticals Inc. has a one year low of $35.53 and a one year high of $50.99. The company has a market cap of $2.97 billion, a P/E ratio of -13.79 and a beta of 1.19.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, beating analysts' consensus estimates of ($0.82) by $0.01. During the same quarter in the prior year, the company posted ($0.73) earnings per share. Analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Blue Trust Inc. raised its stake in Xenon Pharmaceuticals by 174.7% in the 3rd quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company's stock valued at $39,000 after acquiring an additional 641 shares during the period. nVerses Capital LLC bought a new position in shares of Xenon Pharmaceuticals in the third quarter valued at about $102,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Xenon Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company's stock worth $106,000 after buying an additional 487 shares during the last quarter. Quarry LP lifted its stake in shares of Xenon Pharmaceuticals by 207.7% during the 2nd quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company's stock worth $156,000 after buying an additional 2,700 shares during the last quarter. Finally, Vestcor Inc bought a new stake in shares of Xenon Pharmaceuticals during the 3rd quarter worth about $327,000. Institutional investors own 95.45% of the company's stock.
Analyst Ratings Changes
Several research analysts have issued reports on XENE shares. Raymond James reaffirmed an "outperform" rating and set a $50.00 price objective on shares of Xenon Pharmaceuticals in a report on Thursday, October 10th. HC Wainwright reaffirmed a "buy" rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a research note on Thursday, December 12th. Needham & Company LLC reiterated a "buy" rating and issued a $60.00 price objective on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. William Blair raised Xenon Pharmaceuticals to a "strong-buy" rating in a report on Friday, August 30th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $55.00 target price on shares of Xenon Pharmaceuticals in a research note on Tuesday, September 3rd. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $56.33.
Get Our Latest Stock Analysis on XENE
About Xenon Pharmaceuticals
(
Get Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
